Rinascera Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-08.
Rinascera Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 8, 2025. The filing reports $2.50M sold. Its industry group is Biotechnology. It names Nichola Eliovits (Executive Officer, Director), Max Dawson (Executive Officer), Karl Beutner (Executive Officer, Director) (SEC Form D, October 8, 2025).
Is this your company?
Sell to companies like Rinascera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-08 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Rinascera Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Rinascera Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in October 2025, largest first.
Get an email when Rinascera Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Rinascera Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Rinascera Therapeutics, Inc. →Get the full cited report on Rinascera Therapeutics, Inc.
What the filing shows about Rinascera Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Rinascera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Rinascera Therapeutics, Inc.'s address as 75 Kneeland St Fl 14, Boston, MA 02111.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Rinascera Therapeutics, Inc. See pricing
Rinascera Therapeutics, Inc. is a registered filer with the SEC (CIK 2090779) and has filed since 2025-10-08. 1 filing is on record, the latest on 2025-10-08.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Rinascera Therapeutics, Inc.'s Form D of 2025-10-08 names Nichola Eliovits, Max Dawson, Karl Beutner and 1 more as its officers, directors or promoters.
Its new offerings report $2.50M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Rinascera Therapeutics develops transformative therapies for rare genetic skin diseases, including RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic Epidermolysis Bullosa (DEB).
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Nichola Eliovits is named as Executive Officer and Director on the Form D that Rinascera Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 4 people that filing names.
Max Dawson is named as Executive Officer on the Form D that Rinascera Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 4 people that filing names.
Karl Beutner is named as Executive Officer and Director on the Form D that Rinascera Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 4 people that filing names.
Daniel Yadegar is named as Director on the Form D that Rinascera Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 4 people that filing names.
4 people named on the filing — 3 holding an executive role and 1 as a director only.
Named as of the 2025-10-08 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Rinascera Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Rinascera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rinascera Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Rinascera Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Rinascera Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (rinascera.com).
Each opens in a new tab, filled in for Rinascera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/rinascera-therapeutics-inc-form-d-25000001